Leukemia

FDA Approves Gemtuzumab Ozogamicin for CD-33 Positive Acute Myeloid Leukemia

FDA Approves Gemtuzumab Ozogamicin for CD-33 Positive Acute Myeloid Leukemia

By

Gemtuzumab ozogamicin (Mylotarg) was granted US FDA approval for the treatment of relapsed or refractory CD-33 positive AML in patients ages 2 years and older and newly diagnosed CD-33 positive AML in adult patients.

Progression-Free Survival in CLL Prolonged With Maintenance Lenalidomide

Progression-Free Survival in CLL Prolonged With Maintenance Lenalidomide

By

Lenalidomide reduced the relative risk of disease progression in a clinical trial of patients with chronic lymphocytic leukemia who did not achieve MRD negative disease state after first-line chemoimmunotherapy.

Two FDA Approvals Propel CAR T Cell Therapy Into the Limelight

Two FDA Approvals Propel CAR T Cell Therapy Into the Limelight

By

The first FDA approval of a CAR T cell therapy is granted for the treatment of B-cell precursor ALL. FDA also approves rheumatoid arthritis medication for the management of cytokine release syndrome, a common and serious adverse effect of CAR T cell therapy

Inotuzumab Ozogamicin Granted FDA Approval for Acute Lymphoblastic Leukemia

Inotuzumab Ozogamicin Granted FDA Approval for Acute Lymphoblastic Leukemia

By

Inotuzumab ozogamicin (Besponsa), an antibody-drug conjugate comprised of a monoclonal antibody that targets CD22 linked to the cytotoxic agent calicheamicin, was granted FDA approval for the treatment of R/R B-cell precursor ALL.

Utilization of Optimal End-of-Life Care for Acute Myeloid Leukemia Often Delayed

Utilization of Optimal End-of-Life Care for Acute Myeloid Leukemia Often Delayed

Hospice services and effective health care strategies are underutilized by patients with AML leading to suboptimal end-of-life care.

Decitabine Improves Overall Survival, Overall Response Rate in Chronic Myelomonocytic Leukemia

Decitabine Improves Overall Survival, Overall Response Rate in Chronic Myelomonocytic Leukemia

By

Patients with high-risk chronic myelomonocytic leukemia (CMML), a MDS/myeloproliferative neoplasm, may experience prolonged overall survival and increased overall response rate from treatment with decitabine.

Current, Emerging Systemic and Targeted Therapies for Pediatric Leukemia: A Review

Current, Emerging Systemic and Targeted Therapies for Pediatric Leukemia: A Review

By

In this review, investigators discuss current and emerging treatments for acute lymphocytic leukemia and acute myeloid leukemia in pediatric patients.

Midostaurin Improves Survival in Acute Myeloid Leukemia With FLT3 Mutation

Midostaurin Improves Survival in Acute Myeloid Leukemia With FLT3 Mutation

By

Adding midostaurin, a multitargeted kinase inhibitor, to standard chemotherapy provides significant survival benefit for patients with AML and a FLT3 mutation.

Pediatric Acute Lymphoblastic Leukemia Extramedullary Relapse Responds to CAR-T

Pediatric Acute Lymphoblastic Leukemia Extramedullary Relapse Responds to CAR-T

By

Children with extramedullary relapse of CD19+ acute lymphoblastic leukemia experienced a potent and durable response to the immunotherapy.

Standardized Assessment Tool Prevents Chemotherapy-Induced Neurotoxicity

Standardized Assessment Tool Prevents Chemotherapy-Induced Neurotoxicity

By

Standardized tool improved efficiency and thoroughness of patient assessment and documentation of neurotoxicity caused by high-dose cytarabine.

CAR T Cells: Keeping Pace With Adverse Effects of an Emerging Therapy

CAR T Cells: Keeping Pace With Adverse Effects of an Emerging Therapy

By

The oncology nurses' role in monitoring and early recognition of the signs and symptoms of CAR T-cell toxicities is significant considering the potential severity of these adverse effects.

Novel Approach Prevents GVHD After Hematopoietic Stem Cell Transplantation

Novel Approach Prevents GVHD After Hematopoietic Stem Cell Transplantation

By

An international team developed an approach to hematopoietic stem cell transplantation that prevents GVHD while preserving the benefits of the therapy.

Protein Suppresses Transformation of Myelodysplastic Syndrome to Acute Myeloid Leukemia

Protein Suppresses Transformation of Myelodysplastic Syndrome to Acute Myeloid Leukemia

By

Research on the transformation of MDS to AML identifies a protein whose deletion is a potential tumor suppressor that would block this disease progression.

Lasting Outcomes for Imatinib in Chronic Myeloid Leukemia

Lasting Outcomes for Imatinib in Chronic Myeloid Leukemia

The efficacy of imatinib for CML treatment persisted over time and long-term administration was not associated with unacceptable cumulative effects.

Blinatumomab Increased Overall Survival in B-cell Precursor Acute Lymphoblastic Leukemia

Blinatumomab Increased Overall Survival in B-cell Precursor Acute Lymphoblastic Leukemia

By

Results from the TOWER trial demonstrate that blinatumomab (Blincyto) effectively improved OS in high-risk B-cell precursor ALL.

Specialized Cancer Centers May Improve Outcomes in Children with Leukemia

Specialized Cancer Centers May Improve Outcomes in Children with Leukemia

By

The site of cancer care may partially explain survival differences between children and AYAs with ALL.

CRISPR Illustrates Progression of Normal Blood Cells to Leukemia, Precursor Diseases

CRISPR Illustrates Progression of Normal Blood Cells to Leukemia, Precursor Diseases

By

Genome editing technology illustrates progression of normal blood cells to leukemia.

Pediatric Patients, Parents Overreport Adherence to ALL Medication Regimen

Pediatric Patients, Parents Overreport Adherence to ALL Medication Regimen

By

Pediatric patients and their parents tend to overestimate adherence to anticancer medicine regimen.

Lenalidomide Maintenance Appears Efficacious for Relapsed DLBCL

Lenalidomide Maintenance Appears Efficacious for Relapsed DLBCL

By

Lenalidomide maintenance appears efficacious for relapsed diffuse large B cell lymphoma.

Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

By

In a study seeking new therapies to improve outcomes for patients with relapsed or refractory CLL, researchers investigated the impact on progression-free survival of adding idelalisib to bendamustine plus rituximab.

Allogeneic HCT Effective in Older Patients with AML in Second Complete Remission

Allogeneic HCT Effective in Older Patients with AML in Second Complete Remission

By

Researchers determined the curative potential of allogenic hematopoetic stem cell transplantation in patients aged 60 years and older with acute myeloid leukemia in second complete remission.

Two Infants Achieve Leukemia Remission After Gene Therapy

Two Infants Achieve Leukemia Remission After Gene Therapy

By

Two infants with advanced acute lymphoblastic leukemia (ALL) achieved full remission following gene therapy involving modified autologous CAR-T cells.

Frontline Bosutinib Superior to Imatinib for Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase

Frontline Bosutinib Superior to Imatinib for Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase

By

Bosutinib outperformed imatinib as first-line therapy for patients with Ph+ chronic myeloid leukemia in chronic phase, according to trial data.

Researchers Discover Prognostic Genetic Subgroups of a High-Risk Pediatric Leukemia

Researchers Discover Prognostic Genetic Subgroups of a High-Risk Pediatric Leukemia

By

Research from St Jude Children's Research Hospital reveals that acute megakaryoblastic leukemia can be divided into several subgroups with varying prognoses, particularly for children without Down syndrome.

Azathioprine Associated With Increased Risk of Myeloid Neoplasms

Azathioprine Associated With Increased Risk of Myeloid Neoplasms

By

Azathioprine for the treatment of autoimmune disorders is significantly associated with an increased risk of acute myeloid leukemia and myelodysplastic syndromes.

Study Suggest New Treatment Approaches for High-Risk Pediatric Leukemia

Study Suggest New Treatment Approaches for High-Risk Pediatric Leukemia

By

Three specific genetic alterations may help identify pediatric patients with AMKL at high risk who may benefit from allogeneic stem cell transplants.

Arsenic and APL: Review of Therapy for an Acute Leukemia

Arsenic and APL: Review of Therapy for an Acute Leukemia

By

I was surprised to see an order for arsenic recently. What is this being used for?

What Is The Optimal Sequencing of Novel Agents for CLL?

What Is The Optimal Sequencing of Novel Agents for CLL?

By

Ibrutinib appears to be superior first kinase inhibitor for individuals with chronic lymphocytic leukemia, according to a recent real-world study.

Nilotinib for CML Associated With Improved Quality of Life

Nilotinib for CML Associated With Improved Quality of Life

By

Results of this study reveal the impact on quality of life and consequent adherence to therapy for patients with CML-CP receiving nilotinib as second-line therapy.

Adding Pioglitazone to Imatinib May Improve Response in CML

Adding Pioglitazone to Imatinib May Improve Response in CML

By

Researchers evaluated the molecular response in patients with CML-CP treated with pioglitazone in combination with imatinib, the results of which suggest that adding pioglitazone to a kinase inhibitor may have a synergistic effect.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs